Phase I Trial of the Proapoptotic Agonist, LCL161, and Gemcitabine Plus Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Trial Profile

Phase I Trial of the Proapoptotic Agonist, LCL161, and Gemcitabine Plus Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs LCL 161 (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Nov 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
    • 09 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 03 Apr 2014 According to the ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top